Literature DB >> 11420193

Congenital adrenal hyperplasia: management during critical illness.

E Charmandari1, E J Lichtarowicz-Krynska, P C Hindmarsh, A Johnston, A Aynsley-Green, C G Brook.   

Abstract

BACKGROUND: Little is known of the optimal dose and administration schedule of hydrocortisone in critically ill patients with congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency. AIM: To determine plasma cortisol concentrations after intravenous administration of hydrocortisone in children with CAH and to relate these to plasma cortisol concentrations achieved by endogenous secretion in the stress of critical illness in previously healthy children.
METHODS: Plasma cortisol concentrations were measured in 20 patients with classical CAH (median age 11.2 years, range 6.1-16.4) following intravenous administration of hydrocortisone 15 mg/m(2); and in 60 critically ill mechanically ventilated children (median age 2.5 years, range 0.25-16.3) on admission to the paediatric intensive care unit and for 24 hours thereafter.
RESULTS: In the CAH patients, plasma cortisol reached a mean peak of 1648.3 nmol/l (SD 511.9) within 10 minutes of the intravenous bolus, and fell rapidly thereafter; levels remained greater than 450 nmol/l for 2.5 hours only. In critically ill children, mean plasma cortisol on admission to the intensive care unit was 727 nmol/l (SD 426.1). Cortisol concentrations remained raised during the first 24 hours.
CONCLUSIONS: Critically ill patients with classical CAH may be best managed with a single intravenous hydrocortisone bolus followed by a constant rate infusion of hydrocortisone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11420193      PMCID: PMC1718849          DOI: 10.1136/adc.85.1.26

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  5 in total

1.  Reversal of late septic shock with supraphysiologic doses of hydrocortisone.

Authors:  P E Bollaert; C Charpentier; B Levy; M Debouverie; G Audibert; A Larcan
Journal:  Crit Care Med       Date:  1998-04       Impact factor: 7.598

2.  Adrenal insufficiency in septic shock.

Authors:  M Hatherill; S M Tibby; T Hilliard; C Turner; I A Murdoch
Journal:  Arch Dis Child       Date:  1999-01       Impact factor: 3.791

3.  Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.

Authors:  J Briegel; H Forst; M Haller; G Schelling; E Kilger; G Kuprat; B Hemmer; T Hummel; A Lenhart; M Heyduck; C Stoll; K Peter
Journal:  Crit Care Med       Date:  1999-04       Impact factor: 7.598

4.  Diagnosis and management of congenital adrenal hyperplasia.

Authors:  M I New
Journal:  Annu Rev Med       Date:  1998       Impact factor: 13.739

5.  Mortality in patients with congenital adrenal hyperplasia: a cohort study.

Authors:  A J Swerdlow; C D Higgins; C G Brook; D B Dunger; P C Hindmarsh; D A Price; M O Savage
Journal:  J Pediatr       Date:  1998-10       Impact factor: 4.406

  5 in total
  5 in total

1.  Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision).

Authors:  Tomohiro Ishii; Kenichi Kashimada; Naoko Amano; Kei Takasawa; Akari Nakamura-Utsunomiya; Shuichi Yatsuga; Tokuo Mukai; Shinobu Ida; Mitsuhisa Isobe; Masaru Fukushi; Hiroyuki Satoh; Kaoru Yoshino; Michio Otsuki; Takuyuki Katabami; Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2022-04-10

Review 2.  Evaluation of the hypothalamic-pituitary-adrenal axis function in childhood and adolescence.

Authors:  George P Chrousos; Tomoshige Kino; Evangelia Charmandari
Journal:  Neuroimmunomodulation       Date:  2009-06-29       Impact factor: 2.492

Review 3.  Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Felix G Riepe; Wolfgang G Sippell
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

Review 4.  Emergency management of adrenal insufficiency in children: advocating for treatment options in outpatient and field settings.

Authors:  Bradley S Miller; Sandra P Spencer; Mitchell E Geffner; Evgenia Gourgari; Amit Lahoti; Manmohan K Kamboj; Takara L Stanley; Naveen K Uli; Brandy A Wicklow; Kyriakie Sarafoglou
Journal:  J Investig Med       Date:  2019-02-28       Impact factor: 2.895

5.  Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision).

Authors:  Tomohiro Ishii; Makoto Anzo; Masanori Adachi; Kazumichi Onigata; Satoshi Kusuda; Keisuke Nagasaki; Shohei Harada; Reiko Horikawa; Masanori Minagawa; Kanshi Minamitani; Haruo Mizuno; Yuji Yamakami; Masaru Fukushi; Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2015-07-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.